

CURRICULUM VITAE

Marissa E. Magsino, M.D.
Florida Clinical Research Center, LLC
2300 Maitland Center Parkway, Suite 230
Maitland, FL 32751
(407)-644-1165

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Comprehensive Sleep Disorder Center
Altamonte Springs, FL

EDUCATION:

Internal Medicine & Pediatrics
University of Medicine and Dentistry, Newark, NJ 1997

Doctor of Medicine Degree
M.D. University of the East (UERM), Quezon City, P.I. 1986

B.S. Zoology, Pre-Med
University of the Philippines 1982

LICENSURE:

State of Florida # ME 72766

CERTIFICATION:

American Board of Internal Medicine 2001/Recertification 2011
American Academy of Anti-Aging Medicine and Functional Medicine 2009

Curriculum Vitae, Marissa E. Magsino, M.D.

MEDICAL EXPERIENCE:

2009- Present	Bodylogic of Orlando Maitland, FL
2001 – Present	Internal Medicine and Geriatric Care MetroWest Internal Medicine, Orlando, FL
2001	Medical Staff Physician Cigna Healthcare, Altamonte Springs, FL
1997-2000	Hospitalist and Office Staff Physician Physician Associates of Florida, Kissimmee, FL

PROFESSIONAL APPOINTMENTS:

Philippine Medical Association of Central Florida, *President*
American Geriatrics Society, *Member*
American Academy of Home Care Physicians, *Member*
American College of Physicians, Florida Chapter, *Member*
Various Home Health Care Agencies, Orlando, FL, *Medical Director*
CME Division for Phil-AM of Central Florida, *Chairman*

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease • Bone Density • Chronic Bronchitis • COPD
Hypercholesterolemia • Hypertension • Hyponatremia
Irritable Bowel Syndrome • Type 2 Diabetes • Women's Health

CLINICAL TRIAL EXPERIENCE:

Alzheimer's Disease

A 12-week Multi-Center Open Label Study to Evaluate the effectiveness and safety of XXX in Individuals with Mild to Severe Alzheimer's Disease (AD) residing in Assisted Living Facility

Cardiovascular

A Phase IIIb, 12-Month, Double-blind, Double-dummy, Randomised, Parallel-group, Multicentre Exacerbation Study of XXX compared to XXX in COPD Subjects

CLINICAL TRIAL EXPERIENCE (continued):

A Phase IV, Stratified, Randomized, Prospective, Unblinded, Active-control Trial of XXX Tablets Versus XXX for the Treatment of Community-acquired Pneumonia and Versus XXX for the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis

A Phase II, Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg XXX once daily, using 100 mg losartan-potassium once daily as calibrator, for 12 months treatment in patients with mild to moderate hypertension

Endocrinology

A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of XXX in patients with Type 2 diabetes insufficiently controlled with insulin glargine and metformin

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of XXX on top of metformin in Type 2 Diabetes not adequately controlled with metformin

A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Effect of Two Doses of XXX on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy

A multi-center, randomized, placebo-controlled “factorial” design, 12-month study to evaluate the efficacy and safety of XXX and XXX co-administered with all registered XXX strengths ranging from 10 mg to 80 mg in patients with primary hypercholesterolemia

International, Multicenter Study of a Twenty-Eight Week, Open-Label, Titrated Oral XXX Administration in Patients With Chronic Hyponatremia

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of oral XXX capsules in subjects with Euvolemic Hyponatremia

Gastrointestinal

A Phase II, Randomized, Double-blind, Dose-Ranging, Placebo- Controlled Study of XXX in subjects with Irritable Bowel Syndrome

CLINICAL TRIAL EXPERIENCE (continued):

Women's Health

A Phase IIIb/IV, Randomized, Multicenter, Double-blind, Double-dummy, parallel group study of XXX or XXX compared to XXX on the transient Post-Dose Symptoms (PDS) following an *i.v.* infusion of a single dose of XXX 5mg, in postmenopausal women with low bone mass

Other Indications

Autopsy follow-up of subjects previously imaged with XXX PET

A Phase III Study of the Correlation Between XXX PET Imaging and Amyloid Pathology